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and Luwen Zhang‡¶1
From the ‡School of Biological Sciences and ¶Nebraska Center for Virology, University of Nebraska, Lincoln, Nebraska 68588 and
the §Lady Davis Institute for Medical Research, Department of Medicine, McGill University, Montreal, Quebec H3A 2T5, Canada
Kaposi sarcoma-associated herpesvirus (KSHV) is a human
␥-herpesvirus associated with several human malignancies. The
replication and transcription activator (RTA) is necessary and
sufficient for the switch from KSHV latency to lytic replication.
Toll-interleukin-1 receptor (TIR) domain-containing adaptorinducing ␤-interferon (TRIF, also called TIR-domain-containing adaptor molecule-1 (TICAM-1)) is a signaling adaptor molecule that is critically involved in the Toll-like receptor 3
(TLR-3) and TLR-4 signaling pathways for type I interferon
(IFN) production, a key component of innate immunity against
microbial infection. In this report, we find a new mechanism by
which RTA blocks innate immunity by targeting cellular TRIF.
RTA specifically degrades TRIF by shortening the half-life
of TRIF protein. This RTA-mediated degradation is at least
partially mediated through the ubiquitin-proteasome pathway
because proteasome inhibitors as well as knockdown of cellular
ubiquitin expression alleviate the degradation. RTA may not
directly interact with TRIF and may activate TRIF degradation
indirectly through an unknown mediator(s). RTA targets multiple regions of TRIF and may use its ubiquitin ligase domain
for the degradation. In addition, physiological levels of TRIF
protein are down-regulated during KSHV lytic replication when
RTA is expressed. Finally, RTA down-regulates doublestranded RNA-initiated activation of TLR-3 pathway, in the
absence of degradation of IFN regulatory factor 7 (IRF-7). Taken
together, these data suggest that KSHV employs a novel mechanism to block the innate immunity by degrading TRIF protein.
This work may contribute to our understandings on how KSHV
evades host immunity for its survival in vivo.

Kaposi sarcoma (KS)2-associated herpesvirus (KSHV), also
known as human herpesvirus 8 (HHV-8), is a ␥-herpesvirus. It
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is believed to be the etiological agent of KS (1–3). KSHV is also
implicated in the pathogenesis of AIDS-associated primary
effusion lymphoma (also called body cavity-based lymphoma
(BCBL)) and a lymphoproliferative disorder known as multicentric Castleman disease (1, 4, 5).
As with other herpesviruses, KSHV goes through both
latency and lytic replication cycles. The expression of the KSHV
replication and transcription activator (RTA) is necessary and
sufficient for the switch from latency to lytic replication (4, 5).
RTA is an immediate early gene (6 – 8) and a sequence-specific
DNA-binding protein (7–13). RTA also interacts with other
factors to modulate its transcription potential, such as with cellular recombination signal sequence-binding protein-J (RBPJ) (14 –16).
RTA also modulates cellular activities through protein degradation. The proteasome is a multicomponent macromolecule
that is ubiquitous in eukaryotic cells and works as a cellular
machinery for degradation of proteins (17). The proteasome
degradation is usually ubiquitin-dependent involving ubiquitin-activating enzyme E1, ubiquitin-conjugating enzyme E2,
and ubiquitin ligase E3 (17–19). RTA was first documented as
an E3 ligase for degradation of a cellular interferon regulatory
factor 7 (IRF-7) (20). Two more cellular proteins, K-RBP and
Hey, both are repressors of KSHV lytic replication and have
been identified as targets for degradation by RTA with the same
pathway (21, 22).
The host innate immune system is essential for the initial
detection of invading viruses and subsequent activation of
adaptive immunity. Toll-like receptors (TLRs) are a family of
evolutionarily conserved receptors. TLRs are able to recognize
molecular patterns unique to pathogens and activate host
innate immunity against the pathogen (23, 24). One of the
major products from TLR activation is the production of type I
interferons (IFN). IFN is a key component to mount a proper
and robust immune response to a viral infection (25, 26).
Toll-IL-1 receptor (TIR) domain-containing adaptor-inducing IFN-␤ (TRIF), also called TIR domain-containing adaptor
molecule-1(TICAM-1), is an adaptor protein that is involved in
the signaling transduction during the activation of some TLRs,
leading to activation of NF-B and type I IFN (27–29). TLR-3
and TLR-4 seem to be dependent on TRIF for their downstream
cascades (27). Because TRIF is critically involved in TLR and
IFN production, it would be a natural strategy for viruses to
nullify TRIF for their own benefit. Vaccinia virus encodes two
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genes to differentially affect TRIF signaling (30, 31). Also, hepatitis C virus encodes a viral protease that cleaves TRIF (32).
Interestingly, the same viral protease also digests another gene
critically involved in IFN production (33).
IFN inhibits the KSHV replication in vitro (34 –36). TLR-4
has been identified as an important molecule against KSHV
infection, and KSHV has developed a mechanism to rapid suppression of TLR-4 expression (37). Also, murine ␥-herpesvirus
68 (MHV68) is another herpesvirus with significant similarities
to KSHV. Activation of the TLR-3/TLR-4 pathway potently
inhibits the replication of MHV68 in vivo (38). At the same
time, KSHVs have a segment genomic DNA and protein product (K8.1) that induce the production of IFNs (39, 40). KSHV
infects many cell types, including B lymphocytes and dendritic
cells (41– 44). These cells express multiple TLRs, and dendritic
cells are potent IFN producers. Thus, a successful counteraction of IFN activation may be a necessity for the survival of
KSHV in vivo.
KSHV encodes several genes to counteract the innate IFN
response. IRF-7 was first cloned in the context of Epstein-Barr
virus (EBV) latency (45) and is a master gene for IFN production
(46). KSHV employs two mechanisms to nullify the function of
IRF-7; RTA mediates IRF-7 degradation in certain cell lines
(20), and ORF45 blocks the activation of IRF-7 to impair IFN
production (47). In addition, KSHV latency-associated nuclear
antigen (LANA) is able to block the activation of TBK1-mediated activation of IRF-3 (48). KSHV encodes several viral
homologs of the IRF family of transcription factors (vIRF).
vIRF1, vIRF2, and vIRF3 are all able to block the production of
IFNs by functioning as dominant negative versions of cellular
IRFs (4, 5). Furthermore, KSHV ORF10 is also able to block the
IFN signaling in KSHV-infected cells (49).
We have found a cell line in which IRF-7 could not be
degraded by RTA. However, IFN production was still inhibited
by RTA as reported previously (20). We have examined the
mechanism of this IRF-7 degradation-independent IFN inhibition and found that RTA degrades cellular TRIF protein, an
upstream adaptor protein involved in IFN production. This
report provides another mechanism by which KSHV nullifies
host innate immunity.

MATERIALS AND METHODS
Plasmids, Antibodies, and siRNA—Expression plasmids of
KSHV RTA and its mutant (RTA-K152E), EBV RTA, IRF-7,
pcDNA3.1-Myc-TRIF, and p56-luc (561-pGL3 luciferase
reporter construct) are as described previously (45, 50 –54).
FLAG-TLR3 was a gift from Dr. Katherine Fitzgerald (55).
Ubiquitin-expressing plasmid was a gift from Dr. Clinton Jones.
The mutagenesis to generate a mutant with deletion (amino
acids 318 –514; TRIF-Del) was done by the use of PCR sitedirected mutagenesis kit (Invitrogen). The TRIF-N (amino
acids 1–514) and TRIF-C (amino acids 318 –712) were done
with the use of PCR and cloned into 3⫻-FLAG vector (Sigma).
The expression clones were all sequenced to verify the validity
of the clones. IRF-7 antibody was as described previously (45).
Tubulin (T6557) and FLAG antibody (F1804) were obtained
from Sigma. The antibodies for Myc (SC-40), IRF-1 (SC-497),
ubiquitin (SC-9133), and GAPDH (SC-47724) were from Santa
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Cruz Biotechnology. TRIF antibody was from Cell Signaling
(catalog number 4596). siRNA to ubiquitin (siUb) was from
Santa Cruz Biotechnology (SC-29513), and siLuc was from
Thermo Scientific Dharmacon (D-002050-01-05).
Cell Culture—293T is a human fibroblast line. WT11(clone
9) is a TLR-3-expressing cell line (56) (gift from Dr. Ganes Sen).
Both cells were grown in Dulbecco’s modified Eagle’s medium
(DMEM, Invitrogen) supplemented with 10% fetal bovine
serum (FBS; Invitrogen) and 1% penicillin-streptomycin at
37 °C in 5% CO2 incubation. 400 g/ml G418 (Invitrogen) was
used to maintain the TLR-3 expression in WT11 cells. IB4 is a
KSHV-negative but EBV-positive cell line. BCBL1 is a KSHVpositive primary effusion lymphoma line. These cells were
maintained in RPMI 1640 plus 10% FBS.
Transient Transfection, Drug Treatment, and Reporter
Assays—Effectene (Qiagen, Valencia, CA) was used for the
transfection of 293T or WT11-9 cell lines following the manufacturer’s recommendation. Proteasome inhibitors were as follows; lactacystin (80052-806) was from VWR International and
used at the 1–10 M range, and MG132 (HPK-116) was purchased from Assay Designs and used at 1–10 mM. For lactacystin and MG132 treatment, cells were transfected, and medium
were removed 4 – 6 h after transfection. Fresh medium plus
proper concentrations of drugs were added. Cells were collected 12–24 h later. Poly(I-C) (double-stranded RNA) was purchased from InvivoGen (tlrl-pic) and used at 10 g/ml. Luciferase assays were performed using the assay kit from Promega
according to the manufacturer’s recommendation. ␤-Galactosidase assays were also performed for transfection efficiency.
Data were averaged from the triplicates.
Protein Stability Assays—Protein biosynthesis inhibitor,
cycloheximide, was purchased from Sigma (C4859) and used at
50 –100 g/ml. Cells were transfected in 10-cm dishes, and
transfected cells were split 4 – 6 h after transfection into a 6-well
plate. On the next day, the cells were treated with cycloheximide for the indicated period, and cell lysates were made and
used for Western blot analysis.
Western Blot Analysis, RNA Extraction, and RNase Protection Assays (RPAs)—Standard Western blot analysis was performed as described (57–59). Total RNA was isolated from cells
using the RNeasy total RNA isolation kit (Qiagen) or TRIzol
extraction. RPA was performed with 10 g of total RNA using
the RNase protection assay kit II (Ambion, Houston, TX) at
55 °C. Sometimes, gradient temperatures were performed for
RPA when difficulties in RPA were encountered (60). The
GAPDH probe was from United States Biochemicals, Inc. The
probe for IFN-␤ was a gift from Dr. Ganes Sen.

RESULTS
RTA Has an Additional Mechanism(s) to Block the IFN
Production—RTA has been shown to degrade cellular IRF-7 for
the blockage of IFN production (20). We have examined whether
RTA could degrade IRF-7 extensively and found that RTA was
unable to degrade IRF-7 in the cell line we used (293T) (Fig. 1A).
Because RTA blocks the production of IFN, this particular line is
therefore very useful to examine the role of IRF-7 in RTA-mediated IFN production. IRF-7 was transfected with or without RTA,
and the cells were infected by Sendai virus. As shown in Fig. 1B,
VOLUME 286 • NUMBER 10 • MARCH 11, 2011
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FIGURE 1. KSHV RTA blocks IFN production without IRF-7 degradation. A, RTA could not degrade IRF-7 in the 293T cells. IRF-7 expression plasmid (0.1 g)
plus various amounts of RTA (0.2 g) were transfected into 293T cells in a 6-well plate. Total DNA for transfection was maintained the same with the use of
vector DNA (pcDNA3). Lysates were used for Western blot analysis. The identity of proteins is as shown. B, RTA inhibits IFN production. IRF-7 expression plasmid
(0.4 g) plus RTA (0.8 g) were transfected into 293T cells in a 10-cm dish. 1 day later, cells were infected with Sendai virus (20 HA units/ml) for 6 h. Total RNA
was isolated, and RPA was performed with IFN-␤ and GAPDH probes. The identity of RNA is as shown.

FIGURE 2. RTA reduces the expression of TRIF protein. A, RTA reduces TRIF
protein expression. 293T cells in 6-well plates were transfected with pcDNA3,
RTA (0.2 g), and TRIF expression plasmid (0.1 g) in various combinations as
shown on the top. Total DNA for transfection was maintained the same with
the use of vector DNA. The cell lysates were obtained 1 day later for Western
blot analysis. The identity of proteins is as shown. B, EBV RTA could not reduce
the expression of TRIF. 293T cells were transfected with pcDNA3, RTA (0.2 g),
E-RTA (0.2 g), and TRIF expression plasmid (0.1 g) in various combinations
as shown on the top. The cell lysates were obtained 1 day later. The membrane was stripped and probed with another antibody. The images in the
same box indicate that they are derived from the same membranes. The identity of proteins is as shown.

endogenous IFN-␤ production was greatly enhanced with IRF-7
expression. However, with the expression of KSHV RTA, the IFN
production was drastically reduced. The use of IFN-␤ as a marker
for type I IFN production is well established and appreciated in the
field. Because in our experimental system there was no apparent
IRF-7 degradation, even after the 6-h Sendai infection (Fig. 1A and
data not shown), the data suggest that KSHV RTA has an additional mechanism(s), other than degradation of IRF-7, for the
blockage of IFN production.
RTA Reduces the Expression of TRIF Protein—The data in Fig.
1 suggested that RTA blocks transcription of IFN by targeting a
different protein involved in the innate immune response. We
thus examined several intermediates involved in IFN induction
for putative RTA targets, such as TRIF and RIG-I. 293T cells
were co-transfected with target gene and RTA expression plasmids, and 1 day later, the cell lysates were used to examine the
target gene expression. As shown in Fig. 2A, we found that TRIF
MARCH 11, 2011 • VOLUME 286 • NUMBER 10

FIGURE 3. RTA alters the TRIF protein stability. 293T cells in a 10-cm dish
were transfected with TRIF (0.4 g) (A) or TRIF plus RTA (0.8 g) expression
plasmid (B). Total DNA for transfection was maintained the same with the
use of vector DNA. 6 h after transfection, cells were split into a 6-well plate.
Cycloheximide (100 g/ml) was added after a 12-h incubation. Cell lysates
were made at various time intervals (in hours) as shown on the top, and
Western blot analysis was performed. The membrane was stripped and
probed with another antibody. The images in the same box indicate that
they are derived from the same membranes. The identity of proteins is as
shown.

protein was reduced in the presence of RTA. This reduction
seems to be specific for KSHV RTA as EBV RTA (E-RTA) could
not reduce the expression of TRIF at the level expressed (Fig.
2B). EBV RTA and KSHV RTA have significant homologies,
and both viruses are ␥-herpesvirus. We further examined
whether TRIF RNA levels were reduced when RTA was present. The semiquantitative RT-PCR results indicated that TRIF
RNA was not obviously affected by RTA expression (data not
shown). Thus, the data suggest that RTA may reduce TRIF protein expression to block IFN production.
RTA Modulates Protein Stability of TRIF—To test whether
RTA can alter TRIF protein stability, 293T cells were transfected with TRIF, with or without RTA expression plasmid. 1
day later, cells were treated with cycloheximide for blockage of
protein synthesis. Cell lysates were made at various time points
after the drug treatment. As shown in Fig. 3, the TRIF protein
was quite stable at 7 h after treatment. However, the half-life of
TRIF was reduced in the presence of RTA (Fig. 3B). The half-life
JOURNAL OF BIOLOGICAL CHEMISTRY

7867

KSHV RTA Degrades TRIF
of IRF-1 protein was also examined and was short as expected
(61). These results indicated that RTA reduced TRIF expression by altering protein stability.
An RTA Mutant Does Not Significantly Degrade the Expression of TRIF—To determine the region of RTA to promote the
degradation of TRIF, an RTA mutant (RTA-K152E) was used.
This mutant cannot induce the lytic replication of KSHV (50,
62) and fails to induce the degradation of K-RBP (22). As shown
in Fig. 4, the expression of TRIF was significantly reduced in
cells transfected with RTA; however, TRIF expression was partially restored in the cells transfected with RTA-K152E. The
region (amino acids 118 –207; Cys/His-rich domain) was
shown to be the putative domain as E3 ligase for IRF-7 and
other proteins (20, 22). The mutation (K152E) is within the
putative E3 ligase domain.
Multiple Regions of TRIF Are Targeted by RTA—To narrow
down the region(s) of TRIF for RTA-mediated degradation,
we have made several mutants as shown in Fig. 5A. The
TRIF-Del was made to remove the majority of the TIR

FIGURE 4. An RTA mutant failed to reduce the protein expression of TRIF.
293T cells were transfected with vector pcDNA3, TRIF (0.1 g), RTA (0.2 g),
and RTA-K152E (0.1 g) expression plasmid in various combinations as
shown on the top. Total DNA for transfection was maintained the same with
the use of vector DNA. Cell lysates were made 1 day later, and Western blot
analysis was performed. The membrane was stripped and probed with
another antibody. The images in the same box indicate that they are derived
from the same membranes. The identity of proteins is as shown.

domain in TRIF. The TIR domain is a signature and used for
interaction with other proteins in TLR signaling. The deletion mutant was transfected into 293T cells, and whether
RTA degrades the TRIF mutant was examined. As shown in
Fig. 5B, the TIR deletion TRIF was degraded by RTA. Next,
we made mutants containing the N or C terminus of TRIF
and the TIR domain. As shown in Fig. 5C, both TRIF-N and
TRIF-C were degraded in the presence of RTA. However, the
RTA-K152E mutant marginally degraded the proteins. The
RTA mutant also failed to degrade TRIF-Del (data not
shown). These data suggest that the RTA targets multiple
regions of TRIF for degradation.
RTA-mediated TRIF Degradation Is Mediated through
Proteasome—RTA has been shown to degrade several proteins through the proteasome pathway (20, 22). To address
whether TRIF is also degraded through the proteasome, we
first used the proteasome inhibitor lactacystin. As shown in
Fig. 6A, lactacystin partially restored the expression of TRIF.
Another proteasome inhibitor, MG132, also partially
restored the TRIF protein expression (data not shown). Second, we used siUb to knock down the endogenous ubiquitin.
As shown in Fig. 6B, siUb could partially restore the expression of TRIF, but siRNA for luciferase (siLuc) failed to do so.
The expression of ubiquitin was reduced in the presence of
siUb (Fig. 6B). Finally, whether ubiquitin could be added to
the TRIF molecule and increase its molecular weight was
examined. However, we could not detect any slowly migrating, high molecular weight TRIF present under our experimental conditions (data not shown). It is possible that the
TRIF molecule might be too large, and the addition of limited ubiquitin molecule might not be as obvious for observation. We then tested whether the ubiquitination could be
observed in the TRIF-C as it is relatively small in molecular
weight. As shown in Fig. 6C, in the presence of RTA, a slowly
migrating, high molecular weight smear of TRIF-C, was observed (Fig. 6C, lanes 1 and 2). Furthermore, increased levels

FIGURE 5. RTA targets multiple regions of TRIF for degradation. A, schematic diagram of TRIF mutant constructs. The numbers denote the amino acid
positions. The drawing is not to scale. B, TRIF-Del is degraded by RTA. 293T cells were transfected with vector pcDNA3, TRIF (0.1 g), RTA (0.2 g), and TRIF-Del
mutant (0.1 g) expression plasmids in various combinations as shown on the top. Total DNA for transfection was maintained the same with the use of vector
DNA. Cell lysates were made 1 day later, and Western blot analysis was performed. Myc and GAPDH antibodies were used. The identity of proteins is as shown.
C, both TRIF-N and TRIF-C are degraded by RTA. The two TRIF mutants, RTA, and RTA-K152E, were transfected into 293T cells with various combinations. FLAG,
Myc, GAPDH, and RTA antibodies were used for the Western blot. The images in the same box indicate that they are derived from the same membranes. The
identity of proteins is as shown.
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FIGURE 6. RTA degrades TRIF through proteasome pathway. A, proteasome inhibitor alleviates TRIF degradation. 293T cells were transfected with pcDNA3,
RTA (0.2 g), and TRIF expression plasmid (0.1 g) in various combinations as shown on the top. Total DNA for transfection was maintained the same with the
use of vector DNA. 6 h after transfection, cells were washed and treated with lactacystin. The cell lysates were obtained 1 day later for Western blot analysis. The
identity of proteins is as shown. B, knockdown of ubiquitin alleviates TRIF degradation. 293T cells were transfected with pcDNA3, RTA (0.1 g), and TRIF (0.05
g) expression plasmids in various combinations as shown on the top. In addition, siUb or siLuc (5 pmol of each) were also transfected. Cell lysates were made
1 day later, and Western blot analysis with TRIF antibody was performed. The membrane was stripped and probed with another antibody. The images in the
same box indicate that they are derived from the same membranes. The identity of proteins is as shown. C, ubiquitin was added to TRIF-C. TRIF-C or RTA⫹TRIF-C
were transfected with or without HA-Ub expression plasmid. The cell lysates were obtained 1 day later for Western blot analysis. More cell lysates were used for
RTA⫹TRIF-C transfections. Two different exposures of the same membrane are shown. The identity of proteins is as shown.

FIGURE 7. TRIF is down-regulated during KSHV lytic replication. A, the
inverse correlation between the expression of RTA and TRIF. BCBL1 cells were
treated with sodium butyrate (NaButyrate) for 24 h. Cell lysates were made,
and the expression of endogenous proteins was analyzed by Western blot
analysis. The membrane was stripped and probed with another antibody. The
same cell lysates were used, and images in the same box indicate that they are
derived from the same membranes. The identity of proteins is as shown.
B, sodium butyrate did not affect TRIF in KSHV-negative cell line (KSHV⫺). IB4
cells (KSHV⫺) were treated with sodium butyrate for 24 h, and the cell lysates
were made. The expression of TRIF was examined.

of TRIF-C smears were observable when ubiquitin-expressing plasmid was co-transfected (lanes 3 and 4). The expression of ubiquitin was confirmed (data not shown). These
data provided evidence that RTA, at least partially, promoted TRIF degradation via the proteasome pathway.
Expressions of RTA and TRIF Are Inversely Correlated at
Physiological Concentrations—To examine whether RTA could
degrade TRIF under physiological conditions, we induced the
lytic replication process in the KSHV latently infected BCBL
cell line. RTA is not expressed during the viral latency, but it is
a key mediator for the lytic replication. When KSHV-positive
BCBL1 cells were treated with sodium butyrate, the expression
of RTA was significantly increased (Fig. 7A). In addition, a
simultaneous down-regulation of endogenous TRIF expression
was observed. The same lysates were also used for the detection
of IRF-7, and the expression of IRF-7 was increased with the
sodium butyrate treatment, which is in a agreement with a previous report (63, 64). Furthermore, we tested whether TRIF was
degraded in KSHV-negative cell lines. IB4 is an EBV-transformed cell line with no KSHV. With the sodium butyrate treatMARCH 11, 2011 • VOLUME 286 • NUMBER 10

ment, no degradation of TRIF was observed (Fig. 7B). The
induction of lytic replication by sodium butyrate is not 100%.
However, endogenous TRIF is apparently low as we had to concentrate the cell lysates for the detection of endogenous TRIF.
A slight induction of RTA might be sufficient to degrade endogenous TRIF. All these results suggest that the reduction of TRIF
is specifically associated with the induction of KSHV RTA
under physiological conditions.
RTA Down-regulates the Activation of TLR-3 Pathway—Recently, it has been shown that Sendai infection activates the
RIG-I pathway for IFN induction (65). Thus, it is possible that
the IFN blockage observed in Fig. 1 may not be related to TRIF
degradation completely. We thus examined whether RTA
could block a signaling pathway that absolutely requires TRIF.
TRIF is absolutely required for TLR-3 signaling (27). It is well
established that p56 is a good target and a marker of TLR-3
activation (56, 66, 67). We thus tested whether the activation of
p56 promoter by TLR-3 is affected by RTA expression. 293T
cells were transfected with RTA- and TLR-3-expressing plasmids, and transfected cells were treated with or without synthetic double-stranded RNA (dsRNA). As shown in Fig. 8A, p56
promoter reporter was activated in response to TLR-3 and
dsRNA (columns 2 and 3). However, in the presence of RTA, the
activation was drastically reduced (columns 5 and 6). In addition to 293T cells, we also used the TLR-3-expressing cells
(WT11) (56). As shown in Fig. 8B, RTA reduced the dsRNAmediated activation of the p56 promoter reporter. All these
data suggested that RTA reduced TLR-3 signaling activities. Of
note, in our 293T cells, IRF-7 was not degraded by RTA (Fig.
1A). Therefore, the blockage of TLR-3 signaling may be related
to potential TRIF degradation.

DISCUSSION
IFN is important to control KSHV infection, and a successful counteraction of IFN signaling may be a necessity for
the survival of KSHV in vivo. It is thus not surprising that
KSHV encodes several genes to counteract the innate IFN
system. IRF-7 is targeted by at least two KSHV proteins (20,
47). Latency-associated nuclear antigen is able to block the
JOURNAL OF BIOLOGICAL CHEMISTRY
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FIGURE 8. RTA blocks TLR-3 signaling. A, RTA blocks TLR-3 signaling in 293T cells. Various plasmids were transfected into 293T cells as shown on the top. 0.1
or 0.2 g of TLR-3 (columns 2, 3, 5, and 6) was used, respectively. RTA (0.2 g) was used for transfection. Total DNA for transfection was maintained the same with
the use of vector DNA. After 4 – 6 h of transfection, the cells were then treated (⫹) or not treated (⫺) with dsRNA (10 g/ml). 1 day later, the cells were collected,
and luciferase and ␤-gal assays were used for detection of reporter activation. The relative activation of p56 reporter (⫹dsRNA/⫺dsRNA) is as shown. Error bars
indicate S.D. B, RTA blocks TLR-3 signaling in TLR-expressing cells. Various plasmids were transfected into TLR-3-expressing cells (WT11-9) as shown on the top.
0.2 or 0.4 g of RTA was used, respectively. The cells were then treated (⫹) or not treated (⫺) with dsRNA (10 g/ml). The relative activation of p56 reporter
(⫹dsRNA/⫺dsRNA) is shown. One representative result is shown. Error bars indicate S.D.

activation of IFN through IRF-3 (48). KSHV IRF homologs
(vIRF1, vIRF2, and vIRF3) are able to block the production of
IFNs by functioning as dominant negative versions of cellular IRFs. ORF10 blocks the IFN signaling in KSHV-infected
cells (49).
Protein degradation has been shown to be important for
antiviral responses (for a review, see Ref. 68). In this report,
we have shown that RTA could block the IFN production
without degradation of IRF-7 (Fig. 1). To address the possible mechanism behind this IRF-7 degradation-independent
phenomenon, we find that RTA targets TRIF for the blockage of IFN production. First, we show that RTA reduces the
expression of TRIF, and the reduction is likely to be specific
to KSHV RTA as EBV RTA failed to reduce the expression of
TRIF (Fig. 2). Second, RTA affects the stability of TRIF as its
half-life is getting shorter in the presence of RTA (Fig. 3). In
addition, RT-PCR results indicated that TRIF RNA was not
affected by RTA (data not shown). Third, this RTA-mediated
degradation of TRIF seemed to be present under physiological conditions as induction of lytic replication, and thus of
the RTA expression, reduces the expression of endogenous
TRIF protein (Fig. 7). Fourth and finally, the reduction of
TRIF may be responsible for the blockage of TLR-3-mediated activation of p56 promoter in an IRF-7 degradationindependent manner (Figs. 1 and 8).
This RTA-mediated degradation of TRIF is apparently
through the ubiquitin-mediated proteasome pathway. First,
RTA has been shown to be an E3 ligase for the degradation of
IRF-7, Hey1, and K-RBP. We have found that RTA-K152E
mutant lost some activity in degrading TRIF (Figs. 4 and 5). The
same mutant failed to degrade K-RBP (22). Also, the mutation
is located in the Cys/His-rich region (amino acids 118 –207),
the putative E3 ligase domain (20, 22). Second, proteasome
inhibitors (lactacystin and MG132) partially restore the TRIF
protein expression (Fig. 6A and data not shown). Knockdown
of ubiquitin increases the TRIF expression (Fig. 6B). RTA
enhances high molecular weight smear formation in TRIF-C
protein, and the smear is likely to be ubiquitin as the overexpression of ubiquitin enhances the formation (Fig. 6C). All
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these data suggest that RTA degrades TRIF, at least partially,
through ubiquitin-mediated proteasome pathway.
TRIF is a cytoplasmic protein and mainly localized to the cell
membrane (69), and KSHV RTA is a nuclear protein. We have
failed to show that RTA is directly interacting with TRIF in
co-immunoprecipitation assays (data not shown). In addition,
we have done the immunostaining of the two proteins together
in a cell and found that the two proteins were localized to the
cytoplasm and nucleus, respectively, and no obvious co-localization was observed (data not shown). Thus, under our experimental conditions, we failed to obtain convincing evidence
that the two proteins physically interact with each other
directly. However, we cannot exclude the possibility that the
two proteins may interact under some specific conditions/
times. Based on our data, we propose that the RTA-mediated
degradation of TRIF is through an indirect mechanism in which
RTA activates an unknown cellular mediator(s) that facilitates
the degradation of TRIF.
Our results here suggest another novel pathway for KSHV to
evade the host innate immunity. Specifically, TLR-4 has been
identified as an important molecule against KSHV infection
recently, and KSHV has developed a mechanism for rapid suppression of TLR-4 expression (37). TLR-4 activation would lead
to activation of TRIF, which further leads to the induction of
type I IFNs. Therefore, this RTA-mediated degradation of TRIF
may be used by KSHV to escape TLR-4-mediated innate immunity. Finally, the degradation of TRIF was observed in KSHVinfected cells under physiological concentrations (Fig. 7).
Therefore, this phenomenon might naturally occur in individuals who have KSHV infection in vivo. The suppression of
TLR-4 expression as well as TRIF degradation collectively suggest that the TLR-4 pathway is a critical one to control KSHV
infection, and the virus employs two mechanisms to block
TLR-4 activation.
It is known that KSHV infects B cells, where the majority of
TLRs are present (70). In addition, TRIF is an unexpectedly
multifunctional adaptor protein, mediating activation of several transcription factors including NF-B, a key mediator for
pro-inflammatory cytokines (71). Additionally, TRIF may trigVOLUME 286 • NUMBER 10 • MARCH 11, 2011
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ger apoptosis, and thus, degradation of TRIF may alleviate the
potential apoptosis process. It is tempting to speculate that
the RTA-mediated TRIF degradation may not be limited to the
blockage of IFNs, but also other cellular activities for the benefits of KSHV in vivo.
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